Results of the PIONEER-OLE study has shown promising results of mavacamten for patients with obstructive HCM that will be further evaluated in our pivotal phase 3 EXPLORER-HCM trial, said Jay Edelberg, MD, PhD, senior vice president of Clinical Development at MyoKardia.
Results of the PIONEER-OLE study has shown promising results of mavacamten for patients with obstructive HCM that will be further evaluated in our pivotal phase 3 EXPLORER-HCM trial, said Jay Edelberg, MD, PhD, senior vice president of Clinical Development at MyoKardia.
Transcript
What are the most important takeaways from PIONEER-OLE from a health system perspective?
I'm really excited about what PIONEER-OLE is telling us about mavacamten, and more importantly about the promise for patients with obstructive hypertrophic cardiomyopathy or HCM. What we've seen, first of all, is that our patients are able to get their symptoms improved quickly. They go from a New York Heart Association class 2 or class 3, often down to class 1 relatively quickly and stay there for the duration of the trial that we've seen up to 1 year. We've seen that the gradient which is a manifestation of how much that obstruction is, comes down very, very quickly. More than that we're seeing the patients are continuing to do well with their activities of daily living, as measured by the New York Heart Association, and we're seeing some really promising signs. We're seeing that the septum, which is thickened in these patients, is actually getting smaller at progressive points that we're measuring—really exciting what we're seeing.
Can you discuss the design and timeline of EXPLORER-HCM?
EXPLORER-HCM is our pivotal phase 3 program for mavacamten in obstructive hypertrophic cardiomyopathy. In this study, patients are randomized evenly between being treated with mavacamten and placebo. Patients are symptomatic with obstructive HCM, which means that they have an elevated gradient, either at rest or with exercise. They're treated with mavacamten or placebo for 30 weeks and our primary endpoint is to look at improvements in their symptoms and their function, as measured by New York Heart Association class, as well as peak VO2.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More